Tri-Tenbolone Mix

(Intramuscular Injection 200mg/ml)  

Composition

Each 1 ml contains: Trenbolone Enanthate (100 mg), Trenbolone Acetate USP (50 mg), Trenbolone Hexahydrobenzylcarbonate(50 mg), Oily base, ethyl oleate.

Pharmacodynamics

Tri-Trenbolone has both anabolic and androgenic effects. Once metabolized, Tri-Trenbolone esters have the effect of increasing ammonium ion uptake by muscles, leading to an increase in the rate of protein synthesis. It may also have the secondary effects of stimulating appetite and decreasing the rate of catabolism.

Pharmacokinetic

To prolong its elimination half-life, Trenbolone is administered as a prodrug as an ester conjugate such as Trenbolone Acetate, Trenbolone Enanthate, or Trenbolone Hexahydrobenzylcarbonate. Plasma lipases then cleave the ester group in the bloodstream leaving free Trenbolone.Trenbolone and 17-epitrenbolone are both excreted in urine as conjugates that can be hydrolyzed with beta-glucuronidase. This implies that Trenbolone leaves the body as beta-glucuronides or sulfates.

Indications and Usage

Males: SUSTRONE-TT use may be indicated in patients where substantial weight gain and increases in musculature are required for patient health after substantial losses of body mass especially in instances where caloric intake is limited and other anabolic therapies have previously failed. The physician and patient must consider the risks of therapy versus the potential benefits.
Active life: 8 days
Detection time: up to 5 months
Anabolic/Androgenic ratio: 500/500

Side effects

Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; hepatocellular neoplasms, peliosis hepatis, hepatic adenomas, nephritis, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.
Neurological: Increased libido, headache, anxiety, depression, extreme agitation, irritability, and generalized paresthesia. SUSTRONE-TT may cause severe aggressive behavior.

Overdose

In case of adverse effects withdraw use of the drug and immediately call your doctor or pharmacist.

Storage

Store in cool dry place below 30°C, Protect from light. Keep out of reach of children.

Presentation

10 ml. vial is packed in a carton tray. Each carton tray includes 10 ml. vial and information leaflet.